Precision for Medicine acquires Hobart Group Holdings
Precision for Medicine has acquired Hobart Group Holdings, which specializes in strategic communications that address payer needs. Precision for Medicine, which has employees spread across six campuses in the US, launched in 2012 to “support next-generation approaches to drug development and commercialization.”
The Hobart Group started in 2003, and its offices in New Jersey, New York and Chicago, with their headcount of 140 employees, focus on payers, providers and distribution systems. Hobart Group founder Lisa Bair has left the company.
Hobart brings the experience of supporting more than 60 biopharmaceutical brands. “Bridging the value gap that often exists between the pharmaceutical and life sciences industry and its customers requires next generation approaches to scientific evidence, analytics and communications,” Hobart president Dan Renick and now Precision co-president and chief commercial officer said in a statement. “Precision is ideally positioned to help clients address these issues” he added.
Precision CEO Ethan Leder said in a statement that the acquisition addresses “the needs of the patient-centric multipayer landscape that characterizes modern healthcare.”
Neither party was available for comment by press time, so the impact this will have on headcount, if any, is uncertain.